Bcr-Abl inhibition as a modality of CML therapeutics

Elisabeth Buchdunger, Alex Matter, Brian J. Druker

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations

Fingerprint Dive into the research topics of 'Bcr-Abl inhibition as a modality of CML therapeutics'. Together they form a unique fingerprint.